Gawne Peter J, Ferreira Miguel, Papaluca Marisa, Grimm Jan, Decuzzi Paolo
UCL Cancer Institute, University College London, London, UK.
Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary, University of London, London, UK.
Nat Rev Mater. 2023 Dec;8(12):783-798. doi: 10.1038/s41578-023-00581-x. Epub 2023 Jul 26.
Nanoparticle-based systems imbued with both diagnostic and therapeutic functions, known as nanotheranostics, have enabled remarkable progress in guiding focal therapy, inducing active responses to endogenous and exogenous biophysical stimuli, and stratifying patients for optimal treatment. However, although in recent years more nanotechnological platforms and techniques have been implemented in the clinic, several important challenges remain that are specific to nanotheranostics. In this Review, we first discuss some of the many ways of 'constructing' nanotheranostics, focusing on the different imaging modalities and therapeutic strategies. We then outline nanotheranostics that are currently used in humans at different stages of clinical development, identifying specific advantages and opportunities. Finally, we define critical steps along the winding road of preclinical and clinical development and suggest actions to overcome technical, manufacturing, regulatory and economical challenges for the safe and effective clinical translation of nanotheranostics.
具有诊断和治疗功能的基于纳米颗粒的系统,即所谓的纳米诊疗学,在引导局部治疗、对内源性和外源性生物物理刺激产生积极反应以及为患者分层以实现最佳治疗方面取得了显著进展。然而,尽管近年来更多的纳米技术平台和技术已在临床中得到应用,但纳米诊疗学仍面临一些特定的重要挑战。在本综述中,我们首先讨论“构建”纳米诊疗学的多种方式,重点关注不同的成像模式和治疗策略。然后,我们概述目前在临床开发不同阶段用于人体的纳米诊疗学,确定其具体优势和机遇。最后,我们明确临床前和临床开发曲折道路上的关键步骤,并提出行动建议,以克服纳米诊疗学安全有效临床转化过程中的技术、制造、监管和经济挑战。